RxDoctor Payments DataLook up a doctor →

Ajay Gupta, MD

Neurology · Fort Wayne, INNPI 1487651873

Payments from drug & device makers

$2,451,554in general payments, 2019–2025

Across 1,372 payments — averaging $1786.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$857K
  • Sanofi$614K
  • EMD Serono, Inc.$441K
  • Genentech, Inc.$220K
  • Bristol Myers Squibb$96K
  • Biogen$78K
  • plus $145K from 52 others

What the payments were for

  • Consulting fees$62,26015%
  • Speaking & faculty fees$284,12269%
  • Travel & lodging$38,9639%
  • Food & beverage$25,4496%
  • Education$4710%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis100$856,814
Sanofi164$614,356
EMD Serono, Inc.313$440,823
Genentech, Inc.45$219,958
Bristol Myers Squibb76$96,167
Biogen53$77,990
Johnson & Johnson(2 entities)43$35,106
Genentech USA, Inc.84$34,901
TG Therapeutics, Inc.22$25,653
E.r. Squibb & Sons, L.L.C.12$12,469
Eisai Inc.13$12,030
Janssen Research & Development, LLC1$10,000
Greenwich Biosciences, Inc.12$2,608
Mallinckrodt Hospital Products Inc.5$2,060
Banner Life Sciences, LLC15$1,948
AbbVie(2 entities)113$1,183
Jazz Pharmaceuticals Inc.5$989
Ares Trading SA10$850
Amgen(2 entities)25$819
AstraZeneca28$763
Teva Pharmaceuticals USA, Inc.15$481
UCB, Inc.46$382
Lilly USA, LLC21$318
Acadia Pharmaceuticals Inc19$267
Lundbeck LLC12$220
Sanofi-aventis U.S. LLC6$214
Mallinckrodt Enterprises LLC4$206
Sunovion Pharmaceuticals Inc.13$187
Neurocrine Biosciences, Inc.10$180
Supernus Pharmaceuticals, Inc.10$170
CSL Behring8$151
SK Life Science, Inc.7$132
Livanova USA, Inc.8$112
Pfizer5$102
Adamas Pharmaceuticals, Inc.5$81
Amneal Pharmaceuticals LLC5$75
Neurelis, Inc.4$69
Avanir Pharmaceuticals, Inc.4$66
Biohaven Pharmaceutical Holding Company Ltd.3$60
Merz North America, Inc.2$56
Alnylam Pharmaceuticals Inc.2$52
Grifols USA, LLC2$45
Argenx US, Inc.2$42
Tanabe Pharma America, Inc.2$42
MDD US Operations, LLC2$42
Kyowa Kirin, Inc.2$39
Insightec,inc1$29
Bayer2$28
Acorda Therapeutics, Inc2$28
Amylyx Pharmaceuticals, Inc.1$28
Vanda Pharmaceuticals Inc.1$28
Catalyst Pharmaceuticals, Inc.1$24
Vertical Pharmaceuticals, LLC1$23
Otsuka America Pharmaceutical, Inc.1$22
Cala Health, Inc.1$18
GE HealthCare1$17
Medtronic1$17
Zyla Life Sciences, Inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,451,554 in reported general payments places this provider in the 95th percentile of 308 neurology providers in Indiana.

See all neurology providers in Indiana

Medicare billing

Part B allowed, 2024
$2,143,751
Medicare patients
367
Services billed
171,262

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab78$693,388
RebifInterferon Beta-1a/Albumin28$374,988
Teriflunomide80$125,091
GammaplexImmun Glob G(Igg)/Gly/Iga 0-5014$124,552
ZeposiaOzanimod Hydrochloride14$116,589
CopaxoneGlatiramer Acetate16$93,604
Gamunex-CImmune Globul G/Gly/Iga Avg 4624$86,198
IngrezzaValbenazine Tosylate11$81,252
NuedextaDextromethorphan Hbr/Quinidine25$41,287
UbrelvyUbrogepant27$36,812
Glatiramer Acetate13$19,925
Ajovy AutoinjectorFremanezumab-Vfrm15$12,100
Dimethyl Fumarate51$11,025
Dalfampridine ErDalfampridine48$10,944
Emgality PenGalcanezumab-Gnlm11$10,594

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
EMD Serono, Inc.Rebif$440,823$374,98828 claims
E.r. Squibb & Sons, L.L.C.Zeposia$12,469$116,58914 claims
Teva Pharmaceuticals USA, Inc.Copaxone$481$93,60416 claims
Grifols USA, LLCGamunex-C$45$86,19824 claims
Neurocrine Biosciences, Inc.Ingrezza$180$81,25211 claims
Avanir Pharmaceuticals, Inc.Nuedexta$66$41,28725 claims
AbbVieUbrelvy$1,183$36,81227 claims
Amneal Pharmaceuticals LLCMycophenolate Mofetil, Pyridostigmine Bromide$75$6,16069 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 308 neurology providers in Indiana.

Other neurology in Fort Wayne

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →